BBOT - NASDAQ

BO

BridgeBio Oncology Therapeutics Inc.

BBOT·NASDAQ

$8.19

-0.97%
HealthcareBiotechnology

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$656.08M
EPS-4.3000
P/E Ratio-1.90
Earnings Date06/04/2026
BO

BridgeBio Oncology Therapeutics Inc. Fair Value Envelope

BBOT · NASDAQ

Our analysis suggests that BBOT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.19, this represents a potential HIDDEN relative to our calculated worth for BridgeBio Oncology Therapeutics Inc..

HIDDEN
Intrinsic Value
Current Price: $8.19

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$98.2M
+ Cash & Equivalents$373.7M
Firm Value$275.4M
- Debt$2.8M
Equity Value$272.7M
/ Shares Outstanding79,196,710B
DCF Value$3
OVERVALUED BY 58%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$56.9M
-$28.5M
-$14.2M
-$7.1M
-$3.6M
-$1.8M
-$889.8K
-$444.9K
-$222.4K
-$111.2K
Maintenance CapEx
-$60.6K
-$30.3K
-$15.2K
-$7.6K
-$3.8K
-$1.9K
-$947
-$473
-$237
-$118
Owner Earnings
-$57.0M
-$28.5M
-$14.3M
-$7.1M
-$3.6M
-$1.8M
-$890.7K
-$445.4K
-$222.7K
-$111.3K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$52.8M
-$24.4M
-$11.3M
-$5.2M
-$2.4M
-$1.1M
-$519.7K
-$240.6K
-$111.4K
-$51.6K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your BBOT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.